Indeed, chondroitin sulfate proteoglycan (CSPGs/GAPDH) expression (Figure 5A) was higher in the 20-day glioma group (0.48±0.07) compared with 10-day gliomas (0.32±0.09; t=4.663; P<0.01); tenascin C/GAPDH was also markedly increased in the 20- compared with the 10-day counterparts (0.58±0.11 vs 0.29±0.04; t=6.50; P<0.01; Figure 5B). The gene discussed is TNC; the disease is central nervous system cancer.